Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma

Clinical Cancer Research

Volumn 14, Issue 14, 2008, Pages 4640-4649

  Woodard, Jennifer ^a   Sassano, Antonella ^a   Hay, Nissim ^b   Platanias, Leonidas C ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INITIATION FACTOR 4A; INITIATION FACTOR 4E BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN PDCD4; S6 KINASE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; PDCD4 PROTEIN, HUMAN; PROTEIN KINASE; RNA BINDING PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IN VITRO STUDY; KIDNEY CARCINOMA; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; FLOW CYTOMETRY; KIDNEY TUMOR; METABOLISM; PHYSIOLOGY; POLYACRYLAMIDE GEL ELECTROPHORESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; UPREGULATION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FLOW CYTOMETRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOBLOTTING; KIDNEY NEOPLASMS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 51649115883     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5232     Document Type: Article

References (56)

1. Istvan ES, Deisenhofer J. Structural mechanism tor statin inhibition of HMG-CoA reductase. Science 2001;292:1160-4.
2. Toth PP, Davidson MH. Therapeutic interventions targeted at the augmentation of reverse cholesterol transport. Curr Opin Cardiol 2004;19:374-9.
3. Sacks FM, Pfeffer MA, Move LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-9.
4. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-57.
5. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504.
6. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004;291: 1071-80.
7. Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. J Am Med Assoc 1997;278:313-21.
8. Forrester JS, Libby P. The inflammation hypothesis and its potential relevance to statin therapy. Am J Cardiol 2007;99:732-8.
9. Greenwood J, Mason JC. Statins and the vascular endothelial inflammatory response. Trends Immunol 2007;28:88-98.
10. Chan KK, Oza AM, Siu LL. The statins as anticancer agents. Clin Cancer Res 2003;9:10-9.
11. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005;5:930-42.
12. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
13. Wejde J, Hjertman M, Carlberg M, et al. Dolichol-like lipids with stimulatory effect on DNA synthesis: substrates for protein dolichylation? J Cell Biochem 1998; 71:502-14.
14. 1 to multiple cell cycles by lovastatin. Cancer Res 1991;51: 3602-9.
15. Wu J, Wong WW, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res 2004;64:6461-8.
16. Jones KD, Couldwell WT, Hinton DR, et al. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells. Biochem Biophys Res Commun 1994;205:1681-7.
17. Macaulay RJ, Wang W, Dimitroulakos J, Becker LE, Yeger H. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro. J Neurooncol 1999; 42:1-11.
18. Dimitroulakos J, Ye LY, Benzaquen M, et al. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications. Clin Cancer Res 2001;7:158-67.
19. 1 cyclin-dependent kinases. J Biol Chem 2003;278:43586-94.
20. Khanzada UK, Pardo OE, Meier C, Downward J, Seckl MJ, Arcaro A. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signaling. Oncogene 2006;25:877-87.
21. Sivaprasad U, Abbas T, Dutta A. Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells. Mol Cancer Ther 2006;5:2310-6.
22. Kusama T, Mukai M, Iwasaki T, et al. Inhibition of epidermal growth factor-induced Rho A translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Cancer Res 2001;61:4885-91.
23. Kotamraju S, Willliams CL, Kalyanaraman B. Statininduced breast cancer cell death: role of inducible nitric oxide and arginase-dependent pathways. Cancer Res 2007;67:7386-94.
24. Girgert R, Vogt Y, Becke D. Bruchelt G, Schweizer P. Growth inhibition of neuroblastoma cells by lovastatin and L-ascorbic acid is based on different mechanisms. Cancer Lett 1999;137:167-72.
25. Shellman YG, Ribble D, Miller L, et al. Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res 2005;15:83-9.
26. Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses Blood 2003;101:3628-34.
27. Sassano A. Katsoulidis E. Antico G. et al Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 2007;67:4524-32.
28. Longo R, D'Andrea MR, Sarmiento R. Salerno F. Gasparini G. Integrated therapy of kidney cancer. Ann Oncol 2007;6:141-8.
29. Kennedy SG, Wagner AJ, Conzen SD, et al. The PI 3-kinase/Akt signaling pathway delivers an antiapoptotic signal. Genes Dev 1997;11:701-13.
30. Gingras A, Kennedy SG, O'Leary MA, Sonenberg N, Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 199812 502-13.
31. Yetter A, Uddin S, Krolewski JJ. Jiao H, Yi T. Platanias LC. Association of the interferon-dependent tyrosine kinase Tyk-2 with the hematopoietic cell phosphatase. J Biol Chem 1995;270:18179-82.
32. Uddin S, Sassano A, Deb DK, et al. Protein kinase C-δ (PKC-δ is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem 2002;277:14408-16.
33. Colamonici OR, Domanski P, Platanias LC, Diaz MO. Correlation between interferon (IFN) α resistance and deletion of the IFN α/β genes in acute leukemia cell lines suggests selection against the IFN system Blood 1992;80:744-9.
34. Giafis N. Katsoulidis E, Sassano A. et al Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses. Cancer Res 2006;66:6763-71.
35. Kaur S, Lal L, Sassano A, et al. Regulatory effects of mammalian target of rapamycm-activated pathways in type I and II interferon signaling. J Biol Chem 2007; 282:1757-68.
36. Chung M, Calcagni A, Glue P, Bramson C. Effect of food on the bioavailability of amlodipine besylate atorvastatin calcium combination tablet J Clin Pharmacol 2006;46:1212-6.
37. Bhaskar PT Hay N. The two TORCs and Akt Dev Cell 2007;12:487-502.
38. Hay N. The Akt-mTOR tango and its relevance to cancer. Cancer Cell 2005;8:179-83.
39. Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signaling. Nat Rev Immunol 2005;5.375-86.
40. Clark PE. Recent advances in targeted therapy for renal cell carcinoma. Curr Opin Urol 2007;17: 331-6.
41. Hudes G, Carducci M, Tomczak P, et al. Global ARCC Trial. Temsirolimus, interferon a, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356: 2271-81.
42. Fonseca BD, Smith EM, Lee VH-Y, MacKintosh C, Proud CG. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem 2007;282: 24514-24.
43. Nave BT, Ouwens M, Withers DJ, Alessi DR, Shepherd PR. Mammalian target of rapamycin is a direct target for protein kinase B: identification of a convergence point for opposing effects of insulin and amino-acid deficiency on protein translation. Biochem J 1999;344:427-31.
44. Richter JD, Sonenberg N. Regulation of capdependent translation by elF4E inhibitory proteins. Nature 2005;433:477-80.
45. Dorrello NV, Peschiaroli A, Guardavaccaro D, Colburn NH, Sherman NE, Pagano M. S6K1- and βTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. Science 2006; 314:467-71.
46. Cmarik JL, Min H, Hegamyer G, et al. Differentially expressed protein Pdcd4 inhibits tumor promoterinduced neoplastic transformation. Proc Natl Acad Sci U S A 1999;96:14037-42.
47. Yang HS, Knies JL, Stark C, Colburn N. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene 2003;22: 3712-20.
48. Yang HS, Jansen AP, Komar AA, et al. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 2003;23:26-37.
49. McClintock DS, Santore MT, Lee VY, et al. Bcl-2 family members and functional electron transport chain regulate oxygen deprivation-induced cell death. Mol Cell Biol 2002;22:94-104.
50. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 2007;6:541-55.
51. Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8:S62-7.
52. Cho D, Signoretti S, Regan M, Mier JW, Atkins MB. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res 2007;13:758-63s.
53. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxiainducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006;12:122-7.
54. Sjolund J, Johansson M, Manna S, et al. Suppression or renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest 2007;118:217-28.
55. Roudier E, Mistafa O, Stenius U. Statins induce mammalian target of rapamycin (mTOR) -mediated inhibition of Akt signaling and sensitize p53-deficient cells to cytostatic drugs. Mol Cancer Ther 2006;5:2706-15.
56. Finlay GA, Malhowski AJ, Liu Y, Fanburg BL, Kwiatkowski DJ, Toksoz D. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mT0R/S6 kinase activity. Cancer Res 2007;67:9878-86.